1 in 8
Breast cancer context
About one in eight U.S. women will develop breast cancer during her lifetime.
A charitable access pathway
Bringing earlier knowledge within reach.
Liora Life Sciences helps transform private charitable capital into donated hereditary cancer risk assessment Panel Units for deployment through qualified charitable and clinical channels to our underserved and often overlooked communities across the U.S.
Private placement under Rule 506(c). Verified accredited investors only. No economic return. No tax result guaranteed.
The mission
The problem is not the science. It is access.
Hereditary cancer risk can remain hidden within a family for generations. Liora exists to help expand access to hereditary risk information for women who may not otherwise receive testing through ordinary healthcare pathways.
5–10%
Inherited risk
A portion of common cancers is attributable to inherited germline variants.
Earlier
Knowledge matters
Risk information is most useful when it reaches people before a diagnosis defines their choices.
The Program
A single-purpose charitable-donation program.
Liora Life Sciences, LLC is a Delaware limited liability company managed by Liora MGMT, LLC. It acquires, owns, holds, documents, values, and donates complete 36-Gene Female Hereditary Cancer Risk Assessment Panel Units to qualifying public charities.
$50,000
Capital Commitment
Class A Units are available only to verified accredited investors under Rule 506(c) through the controlling offering documents.
80%
Panel acquisition
Approximately $40,000 per Unit is applied to acquire Panel Units. The Company pays the Panel Supplier directly under the Managing Member’s direction.
20%
Expense Allocation
No more than $10,000 per Unit supports permitted Program expenses. The Managing Member charges no management fee.
Audit Defense Reserve: A portion of the Expense Allocation may fund eligible legal and accounting costs associated with defending Members’ charitable deductions. It is not insurance, a tax guarantee, or reimbursement of an adverse tax result, and no unused portion is returned to Members.
How it works
A clear path from capital to charitable deployment.
Liora acquires, owns, documents, values, and donates pooled Panel Units. Qualified charities and clinical counterparties control charitable and clinical deployment.
01 · Capital
Member capital commitments fund the program.
02 · Acquisition
Liora acquires and owns pooled Panel Units.
03 · Donation
Panel Units are donated to qualifying public charities.
04 · Deployment
Donees and clinical channels may reach eligible women at no cost.
05 · Records
Appraisal, donation, acknowledgment, and reporting records support the process.
The Panel
A hereditary-risk assessment tool—
not a cancer diagnosis.
The 36-Gene Female Hereditary Cancer Risk Assessment Panel Unit is a unitized commercial testing product designed to identify selected inherited germline variants associated with elevated risk for certain cancers affecting women.
Important distinction: The Panel does not screen for, detect, confirm, or diagnose active cancer or any disease.
- Physical product: a Collection Kit, included logistics, and contractual Panel Fulfillment Rights.
- Defined assay: evaluation of selected inherited variants across a 36-gene panel.
- Clinical interpretation: qualified healthcare professionals communicate results, counsel patients, and determine follow-up.
- Charitable access: deployment is handled by qualified donees and appropriate clinical channels.
Defined roles
Boundaries create credibility.
Liora is not a laboratory, medical practice, genetic counselor, diagnostic service, clinical outreach provider, or patient-care provider.
Liora
Acquires, owns, holds, documents, values, and donates Panel Units as pooled Company property.
Public charities
Receive donated Panel Units for related exempt use and deploy them through appropriate charitable programs.
Laboratories and clinicians
Handle testing, reporting, authorization, consent, counseling, referrals, and clinical follow-up.
Professional support ecosystem
Defined expertise supports
disciplined administration and reporting.
Liora is supported by experienced independent service providers with clearly defined responsibilities.
Compliance Administrator
PHA
Precision Health Administration, LLC supports subscription, AML/KYC, accreditation, records, reporting, and compliance administration.
Non-discretionary administrative support; no legal, tax, investment, medical, or valuation advice to Members.
pha-us.comAdministrator
EFSI
Fund administration, books and records, accounting, reporting, capital-account and investor reporting support.
Independently owned; SOC 1 compliant; more than $5.5B in assets under administration.
essentialfsi.comPlatform Advisor
LPx
Private-fund reporting and investor-relations platform supporting subscriber onboarding, investor access, document flow, permissions, communications, and shared reporting data.
Designed for alternative investments; MFA-enabled 24/7 access and one shared source of truth. Public site reports 170+ investment vehicles, 3,400+ active monthly users, and $3.7B in assets reported on.
lpx.fundAudit / Tax Reporting
CBIZ LLP
CBIZ LLP provides audit, attest, tax-package, accounting, and reporting support as engaged by the Company.
Members must rely on their own independent tax, legal, accounting, financial, and medical advisors.
cbiz.comRole clarity supports the mission: defined responsibilities, controlled records, and advisor-led review. Provider roles remain subject to engagement terms and the governing documents.
For CPAs & Professional Advisors
Independent advice remains essential.
The Company expects to report each Member’s allocable share of the charitable contribution on Schedule K-1. Deductibility depends on each Member’s individual circumstances and is subject to applicable Code limitations, substantiation requirements, and potential IRS challenge.
Substantiation
The reporting package is expected to include relevant appraisal, acknowledgment, Form 8283, and Schedule K-1 materials, as applicable.
Valuation ceiling
The anticipated reported amount per Panel will not exceed the lesser of $6,375 or the fair market value determined by the Qualified Appraiser.
Advisor’s role
Each Member relies on independent legal, tax, financial, and accounting advisors to determine whether and to what extent any deduction applies.
Any tax analysis prepared for the Company is subject to its own assumptions, qualifications, and reliance limitations. Nothing on this website is a tax opinion or may be relied upon by a prospective subscriber, Member, or advisor.
Accredited Investor Access
Confirm your accredited status.
This offering is conducted under Rule 506(c) of Regulation D and is available only to verified accredited investors.
Are you an accredited investor?
Under Rule 506(c), the Company is required to take reasonable steps to verify that every purchaser is an accredited investor. This first step is your attestation; independent verification follows.
Data Room Access
Request the Program materials.
The controlled data room contains the Private Placement Memorandum, Operating Agreement, Subscription Agreement, and supporting materials.
Controlled access: Access is provided only through the Program’s verification and permissioning process. Submitting a request does not deliver offering documents, constitute an offer, or create an obligation on either side.
Once identity and accredited-investor status are independently verified, credentialed access may be issued through the secure platform with appropriate permissions.
Access to Program materials does not make any Company analysis an opinion for, or advice to, the recipient. Each prospective subscriber must rely on independent professional advisors.
Important notice
The Units offered have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state, and are being offered and sold in reliance on an exemption under §4(a)(2) of the Securities Act and pursuant to Rule 506(c) of Regulation D. This offering is available only to persons who are verified “accredited investors.”
This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offer is made solely to verified accredited investors through the Company’s Private Placement Memorandum and definitive Subscription Agreement, which control in all respects. Members receive no investment return; the only potential benefit is a charitable tax deduction based on each Member’s own advisor’s advice.
The Company does not promise or guarantee any charitable deduction, or that a deduction may be taken under §170 of the Internal Revenue Code. Nothing on this site is legal, tax, or investment advice. Prospective participants should consult their own advisors and review the complete Risk Factors in the Private Placement Memorandum before making any contribution decision.
The Panel identifies certain inherited germline variants that may be associated with elevated risk for specified cancers. It is not a medical or clinical service and does not screen for, detect, confirm, or diagnose active cancer or any other disease.
Liora Life Sciences, LLC
Bringing Light to Tomorrow
Bringing Light to Tomorrow
© 2026 Liora Life Sciences, LLC. All rights reserved.
Rule 506(c) · Verified accredited investors only
Rule 506(c) · Verified accredited investors only